The project is called BrainCure: Medicina de precisión personalizada para las ENACH (BrainCure: personalised precision medicine for NBIA disorders). It has been developed by the scientific team led by the UPO lecturer José Antonio Sánchez Alcázar and is one of the four projects selected by the Spanish Foundation for Rare Diseases (FEDER) in the V Convocatoria de Ayudas a la Investigación (fifth official announcement for research grants). Its resolution has been evaluated by the Carlos III Health Institute.
Etiqueta: ENACH Association
Universidad Pablo de Olavide researchers come up with pantothenate kinase-associated therapeutic solution to palliate neurodegeneration
The scientific research team from the Universidad Pablo de Olavide led by doctor José Antonio Sánchez Alcázar has published a new study in the international magazines Molecular Neorubiology and Neural Regeneration Research. The study suggests therapeutic solutions for pantothenate kinase-associated neurodegeneration (PKAN), which is one of the 12 subtypes of the so-called rare disease NACH that affects children in their first decade of life.